Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fresolimumab

Next Previous
X
Search
Drug Profile

Fresolimumab

Alternative Names: GC-1008

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Baylor College of Medicine; Sanofi
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fibrosis; Malignant melanoma; Osteogenesis imperfecta; Pulmonary fibrosis; Renal cancer
  • Discontinued Focal segmental glomerulosclerosis

Most Recent Events

  • 04 Jul 2022 Baylor College of Medicine in collaboration with Genzyme completes a phase-I clinical trial in Osteogenesis imperfecta in USA (IV) (NCT03064074)
  • 28 Aug 2020 No recent reports of development identified for phase-I development in Osteogenesis-imperfecta in USA (IV)
  • 15 Jul 2017 Phase-I clinical trials in Osteogenesis imperfecta in USA (IV) (NCT03064074)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top